Get the latest news alerts: at Twitter.

Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – Frank Malinoski, a 20-year executive in life sciences, is the new chief medical officer at

Liquidia is seeking to develop nanotechnology-based vaccines and other drugs.

“Frank’s scientific expertise and impressive track record developing and commercializing successful vaccines will be invaluable as we advance our initial vaccine candidate through clinical trials and expand our pipeline of vaccine and therapeutic products,” said Liquidia Chief Executive Officer Neal Fowler.

Malinoski has worked at Wyeth, MedImmune, Nabi and other companies in clinical research, business development and medical affairs. He received a medical degree at Albany Medical College and a PhD in microbiology at Rutgers University.